Journal
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
Volume 9, Issue -, Pages -Publisher
FRONTIERS MEDIA SA
DOI: 10.3389/fbioe.2021.650376
Keywords
mesenchymal stem cells; exosomes; dexamethasone; autoimmune hepatitis; delivery
Funding
- National Natural Science Foundation of China [81871912, 81970530]
- Shanghai Municipal Health Bureau Key Disciplines Grant [ZK2019C012]
Ask authors/readers for more resources
Exosomes, particularly Exo@DEX, have shown promising potential as a drug carrier for autoimmune hepatitis (AIH) by efficiently improving the accumulation of dexamethasone (DEX) in the liver, suggesting potential applications in other diseases as well.
Exosomes (Exos) are nanosized vesicles (around 100 nm) that recently serve as a promising drug carrier with high biocompatibility and low immunogenicity. Previous studies showed that Exos secreted from mesenchymal stem cells (MSCs) provide protection for concanavalin A (Con A)-induced liver injury. In this study, the protective effect of Exos is confirmed, and dexamethasone (DEX)-incorporated Exos named Exo@DEX are prepared. It is then investigated whether Exo@DEX can function more efficiently compared to free drugs and naive Exos in a Con A-induced autoimmune hepatitis (AIH) mouse model. The results show that Exo@DEX efficiently improves the accumulation of DEX in AIH in the liver. These data suggest that Exo@DEX is a promising drug carrier for AIH and could have applications in other diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available